Life Science Corp | NK cellular therapy

Science

LIFE

LIFE
Sciences

NK LIFE

Gamma LIFE

ALPHA LIFE

AI LIFE

Extending Human Lifespan
by 30 Years

Technology Platform I

Universal CAR NK engineered with base editing to target

cellular senescence and tumors

Technology Platform II

Human bioenergy based biophysical and digital therapy

Technology Platform III

Novel LNP/mRNA nanovaccines for CNS and cancer

Pipeline

Anti-Aging

LIFE Sciences Corp is determined to extend human lifespan by 30 years through three subsidiary companies with three distinct innovative platforms:

Anti-cancer immunotherapy with genetically engineered "Off the Shelf" CAR NK cells. (NK LIFE)
Anti-aging intranasal nanovaccine and nanomedicine for Alzheimer's & Parkinson's. (ALPHA LIFE)
Human bioenergy based digital therapy for Parkinson's Disease. (GAMMA LIFE)

We also utilize immuno-senolytic CAR NK targeting cellular senescence (aging cells) for the treatment of cardiomyopathy. And we develop calorie restriction mimics targeting mitochondrial metabolism.

Cell and gene therapy: blood Tumor

Cell and gene therapy: solid Tumor

MKureTM for the treatment of BCMA exposed/relapsed MM is a CAR-NK therapy which contains a proprietary GPRC5D nanobody derived from llama. Pending in vivo efficacy and safety data in animals, NKLife plans for an IND submission in US in 1H26. MKureTM has a strong IP portfolio which consists of the GPRC5D nanobody, the genetically designed CAR sequence, and the proprietary technology involved in bioprocessing NK cells from healthy donors.

BKURETM is a CAR-NK with a llama derived nanobody against ROR1 for the treatment of triple negative breast cancer.

GKURETM is a CAR-NK with a llama derived nanobody raised against Claudin6 for the treatment of gastric cancer.

DKURETM is a Dendritic Cells (DC) targeted LNP formulation that can deliver mRNA encoding tumor antigen directly to the lymph nodes to generate anti-tumor T cell responses.